Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
22
Not yet recruiting, industry sponsors, Respiratory, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed890
22 trials
Showing 1 to 22, recently updated first.
- Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)Pivotal-lookingNot yet recruiting
Primevera Therapeutics, LLC.Industry
NCT07191535 · 237 participants (planned) · Start Mar 1, 2027 · Primary completion Mar 1, 2028
Drug: linvemastat; Placebo · For: Asthma (Diagnosis); Pulmonary Function; Moderate-to-Severe Asthma
Sites: Newark, Delaware
- A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07926321 · 70 participants (planned) · Start Nov 13, 2026 · Primary completion Jan 27, 2028
Drug: BI 3810477 · For: Idiopathic Pulmonary Fibrosis
Sites: Tucson, Arizona; Newport Beach, California; Palo Alto, California · 42 sites in all
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
CSPC-NBP Pharmaceutical Co., Ltd.Industry
NCT07933133 · 300 participants (planned) · Start Dec 1, 2026 · Primary completion Apr 1, 2029
Drug: SYH9061; Placebo and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Guangzhou, China
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNot yet recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07909655 · 75 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: HB0056; HB0056 and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Changsha, China; Shanghai, China
- A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary DiseaseNot yet recruiting
SMSbiotechIndustry
NCT07871890 · 125 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 2027
Drug: Stem cells · For: Chronic Obstructive Lung Disease
Sites: Miami, Florida
- A Trial of AGMB-447 in Participants With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
Agomab Spain S.L.U.Industry
NCT07862634 · 120 participants (planned) · Start Nov 30, 2026 · Primary completion Oct 31, 2028
Drug: AGMB-447; Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
- CS1 Added to Standard of Care Therapy for Pulmonary Arterial HypertensionPivotal-lookingNot yet recruiting
Cereno Scientific ABIndustry
NCT07761572 · 126 participants (planned) · Start Sep 15, 2026 · Primary completion Feb 2, 2029
Drug: CS1; Placebo · For: Pulmonary Arterial Hypertension
- Study on Doses of Inhaled ALX1 in Adults With BronchiectasisNot yet recruiting
Vast TherapeuticsIndustry
NCT07731919 · 28 participants (planned) · Start Sep 1, 2026 · Primary completion Mar 31, 2027
Drug: ALX1; Placebo · For: Bronchiectasis Adult
- Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07728721 · 175 participants (planned) · Start Aug 25, 2026 · Primary completion Apr 10, 2028
Drug: HSK50042 dose 1; HSK50042 dose 2 and 2 more · For: Idiopathic Pulmonary Fibrosis (IPF)
- A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
InnovStone Therapeutics LimitedIndustry
NCT07600021 · 156 participants (planned) · Start Jun 30, 2026 · Primary completion Oct 30, 2027
Drug: SYH2059 Tablets; Placebo · For: Idiopathic Pulmonary Fibrosis
Zhejiang Kanova Biopharmaceutical Co., LTDIndustry
NCT07519499 · 75 participants (planned) · Start Apr 1, 2026 · Primary completion Dec 1, 2027
Drug: XKH001Injection; Placebo · For: COPD
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With AsthmaPivotal-lookingNot yet recruiting
AkesoIndustry
NCT07436221 · 160 participants (planned) · Start Feb 28, 2026 · Primary completion Dec 27, 2026
Drug: AK139; AK139 and 2 more · For: Asthma
Sites: Guangzhou, China; Shanghai, China
- Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPDNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07425210 · 300 participants (planned) · Start Mar 2026 · Primary completion Jul 2027
Drug: HSK39004 Dry Powder Inhaler -0.75mg BID · For: Chronic Obstructive Lung Disease (COLD)
Sites: Guiyang, China
- A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPDPivotal-lookingNot yet recruiting
Ganzhou Hemay Pharmaceutical Co., LtdIndustry
NCT07314242 · 120 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2027
Drug: Hemay005 tablets; Roflumilast Oral Tablet and 1 more · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Tianjin, China · 2 sites in all
- A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaPivotal-lookingNot yet recruiting
Advagene Biopharma Co. Ltd.Industry
NCT07250594 · 126 participants (planned) · Start Dec 2025 · Primary completion Oct 2026
Drug: AD17002 · For: Eosinophilic Asthma
Sites: Taipei, Taiwan
- Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)Not yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07019090 · 120 participants (planned) · Start Jun 27, 2025 · Primary completion Oct 31, 2026
Drug: HSK44459 · For: Idiopathic Pulmonary Fibrosis (IPF)
- A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06980142 · 204 participants (planned) · Start Jun 20, 2025 · Primary completion Mar 17, 2028
Drug: CM512; Placebo · For: Chronic Obstructive Pulmonary Disease
- A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of BronchiectasisPivotal-lookingNot yet recruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT06958861 · 180 participants (planned) · Start May 2025 · Primary completion May 2027
Drug: Low-dose H057+standard-of-care; High-dose H057+standard-of-care and 1 more · For: Acute Exacerbations of Bronchiectasis
Sites: Fuyang, China; Hefei, China; Fuzhou, China · 19 sites in all
- Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With AsthmaNot yet recruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06940700 · 60 participants (planned) · Start Apr 2025 · Primary completion Oct 2025
Drug: SHR4597; Budesonide inhalant · For: Asthma
Sites: Chengdu, China
- A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPDPivotal-lookingNot yet recruiting
Aer TherapeuticsIndustry
NCT06731959 · 100 participants (planned) · Start Dec 2024 · Primary completion Nov 2025
Drug: Flexlamose; Placebo · For: COPD
- A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06547333 · 884 participants (planned) · Start Sep 13, 2024 · Primary completion Apr 29, 2032
Drug: CM310; Placebo · For: Chronic Obstructive Pulmonary Disease
- Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractPivotal-lookingNot yet recruiting
Inmunotek S.L.Industry
NCT05641272 · 90 participants (planned) · Start Nov 1, 2023 · Primary completion Jun 1, 2026
Drug: 3,000 MM09; 9,000 MM09 · For: Allergic Rhinitis; Allergic Asthma; Allergic Rhinoconjunctivitis and 1 more
Sites: Buenos Aires, Argentina
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.